May 4, 2011 – Researchers from the University of Cincinnati presented results from a prospective study at the American Roentgen Ray Society 2011 annual meeting this week, demonstrating how positron emission mammography (PEM)-guided biopsy may expedite pre-operative work-up and reduce radiation exposure for breast cancer patients.

PEM scanners are high-resolution breast PET systems that can show the location as well as the metabolic phase of a lesion. This information is critical in determining whether a lesion is malignant and influences the course of treatment. Naviscan’s Stereo Navigator Accessory is the first commercialized PET-guided biopsy tool and has been U.S. Food and Drug Administration (FDA)-cleared since 2008.

"PEM is useful for performing local staging in women with newly diagnosed breast cancer,” said Amy Argus, M.D., assistant professor of radiology and one of the lead investigators of the study. “When additional breast abnormalities are identified by PEM, accurate PEM-guided biopsy can be performed on the same day as the diagnostic imaging, which decreases the patient's radiation dose and may expedite their preoperative work-up."

In this study, 18 women with breast cancer classified as BIRADS 5 identified on mammography or ultrasound underwent a PEM scan and same day PEM-guided biopsy on 24 index and satellite lesions. Lesion size was 4-60 mm with a mean size of 16 mm. Results were concordant for 83 percent of lesions and discordant for the remaining due to patient movement and operator experience. PEM is the only technology where physicians are able to biopsy on the same injection of the radiotracer. This is because the radiotracer utilized, FDG, does not washout of the tumor as with other blood flow-dependant modalities like MRI or BSGI. By avoiding a double injection of radiotracer, the radiation exposure to the patient and medical personnel is reduced. Same day procedures are also feasible with PEM given the ease of interpretation compared to other advanced imaging modalities.

For more information: www.naviscan.com


Related Content

News | Women's Health

Feb.23, 2026 — The first clinical patient received a Clairity Breast cancer risk score, marking a historic milestone in ...

Time February 23, 2026
arrow
News | Breast Biopsy Systems

Feb. 18, 2026 — Mammotome, a Danaher company, has introduced the Mammotome Prima MR Dual Vacuum-Assisted Breast Biopsy ...

Time February 18, 2026
arrow
News | Breast Imaging

Feb. 16, 2026 — Rising demand for breast cancer screening and diagnostics is outpacing the supply of available breast ...

Time February 17, 2026
arrow
News | Radiology Imaging

Feb. 12, 2026 — Siemens Healthineers and Mayo Clinic are expanding their strategic collaboration to enhance patient care ...

Time February 13, 2026
arrow
News | FDA

Feb. 2, 2026 — Imagion Biosystems, Ltd. has submitted an Investigational New Drug (IND) application with the U.S. Food ...

Time February 02, 2026
arrow
News | Breast Imaging | Washington University

Jan. 22, 2026 — In breast cancer, a biopsy is the only diagnostic procedure that can determine if a suspicious lump or ...

Time January 29, 2026
arrow
News | PET Imaging

Jan. 26, 2026 — Nuclidium, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

Time January 27, 2026
arrow
News | Mammography

Jan. 16, 2026 — Vega Imaging Informatics has announced the successful curation of the world’s largest digital breast ...

Time January 19, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — VizMark has received U.S. Food and Drug Administration FDA 510k clearance for VM1, a non-metal visual ...

Time January 19, 2026
arrow
News | Radiation Oncology

Jan. 8, 2026 — RefleXion Medical, an external-beam theranostic oncology company, has announced the U.S. Food and Drug ...

Time January 13, 2026
arrow
Subscribe Now